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Nurse-led monitoring of patients for signs and symptoms associated with documented
‘undesirable effects’ of medicines has potential to prevent avoidable harm, and optimise
prescribing.
Intervention
The Adverse Drug Reaction Profile for polypharmacy (ADRe-p) identifies and documents
putative adverse effects of medicines commonly prescribed in primary care. Nurses address
some problems, before passing ADRe-p to pharmacists and prescribers for review, in con-
junction with prescriptions.
Objectives
We investigated changes in: the number and nature of residents’ problems as recorded on
ADRe-p; prescription regimens; medicines optimisation: and healthcare costs. We explored
aetiologies of problems identified and stakeholders’ perspectives.
Setting and participants
In three UK care homes, 19 residents completed the study, December 2018 to May 2019.
Two service users, three pharmacists, six nurses gave interviews.
Methods
This mixed-method process evaluation integrated data from residents’ ADRe-ps and medi-
cines charts, at the study’s start and 5–10 weeks later.
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Results
We recruited three of 27 homes approached and 26 of 45 eligible residents; 19 completed
ADRe-p at least twice. Clinical gains were identified for 17/19 residents (mean number of
symptoms 3 SD 1.67, range 0–7). Examples included management of: pain (six residents),
seizures (three), dyspnoea (one), diarrhoea (laxatives reduced, two), falls (two of five able
to stand). One or more medicine was de-prescribed or dose reduced for 12/19 residents.
ADRe administration and review cost ~£30 in staff time. ADRe-p helped carers and nurses
bring residents’ problems to the attention of prescribers.
Implications
ADRe-p relieved unnecessary suffering. It supported carers and nurses by providing a tool
to engage with pharmacists and prescribers, and was the only observable strategy for multi-
disciplinary team working around medicines optimisation. ADRe-p improved care by: a) reg-
ular systematic checks and problem documentation; b) information transfer from care home
staff to prescribers and pharmacists; c) recording changes.
Registration
NLM Identifier NCT03955133; ClinicalTrials.gov.
Introduction
The scale and complexity of inadvertent iatrogenic harm from both use and misuse of
medicines underlie the World Health Organisation’s (WHO) Third Global Patient Safety
Challenge—to reduce avoidable medication-related harm by 50% by 2022 [1]. Structured,
multi-faceted, multi-professional interventions have an important role in mitigating risk, nota-
bly in primary and community care, where the WHO recognises a dearth of interventions to
improve patient safety. Our intervention, the Adverse Drug Reaction (ADRe) Profile [2–4],
achieves this by uniting the tacit, experiential knowledge of nurses and carers with records of
the patients’ clinical problems and possible causes, in a form that can be shared within the
multidisciplinary team [2–7] (Fig 1).
Fig 1. How ADRe works.
https://doi.org/10.1371/journal.pone.0244519.g001
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Background
Identification of medicine-related incidents as the most prevalent source of unsafe primary
care in Wales and England underlines the urgency of the need for a solution [8]. Patient
safety incidents due to acts of commission, excluding acts of omission, arise in 1–24 of every
100 primary care consultations, mainly due to misdiagnoses or medicines mismanagement;
up to 44% of these lead to severe harm [9]. Both inappropriate- and under-prescribing
increase mortality rates and hospital admissions [10]. Up to 92% of ADEs, adverse drug reac-
tions (ADRs), and medicines’ mismanagement (including patient safety incidents where
patients and professionals contribute) are preventable [11–14]; more are due to poor moni-
toring than poor prescribing [15–19] and are dose-related [20,21]. Enhanced patient moni-
toring and/or reviewing would enhance efforts to ameliorate, if not resolve, the situation
[9,16,17,19,22].
In the UK, 2008–11, 49% (of 7359) of older people (>64) took >4 medicines, up from 12%
(of 7,614) in 1991–5, whilst the proportion taking zero medicines fell from 20% to 8% [23] and
emergency admissions for adverse effects of medicine rose [24]. Life expectancy is no longer
rising [25]. Regulation of primary care by incentivisation via the Quality and Outcomes
Framework (QOF) did little to improve patient outcomes, despite considerable investment
[26].
There is little evidence that existing interventions to improve the appropriateness of poly-
pharmacy in older people improve outcomes [27]. Pharmacist-led innovations in pharmaceu-
tical care and computerised decision support improve prescribing but not outcomes [27–32],
and single-problem initiatives may be ineffective [33]. However, nurses’ and carers’ contribu-
tions to medicines optimisation remain unexplored.
Comprehensive, systematic multi-professional approaches are needed to ameliorate iatro-
genic harm from ADRs [2–4]. In trials and observation studies, the ADRe Profiles for mental
health medicines and respiratory medicines improved the processes and outcomes of care and
medicines use for care home residents [4–6], and outpatients [7]. ADRe for polypharmacy
(ADRe-p) was developed because we knew nurses’ and patients’ concerns about ADRs from
mental health medicines were seldom recognised or communicated to prescribers unless
ADRe was used [2,3]. In this study we sought to ‘spread’ the intervention to another geograph-
ical region, and to people prescribed multiple medicines [34].
Aims
We aimed to investigate how deployment of ADRe-p changed: 1) residents’ clinical wellbeing,
measured as the number and nature of patients’ problems and care quality as recorded on
ADRe-p and in care records; 2) prescription regimens; 3) medicines optimisation; and 4)
healthcare resource use. We also explored the aetiologies of problems identified and stakehold-
ers’ perspectives of the ADRe-p initiative.
Methods
Study design
This mixed-method process evaluation integrated and explored data from residents’ ADRe-ps,
medicines administration record (MAR) charts and care home records, at the start of the
study and 5–10 weeks later, plus semi-structured interviews with healthcare professionals and
service users. We followed SQUIRE (Standards for Quality Improvement Reporting Excel-
lence) 2.0 [35] (S1 File).
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Setting
Between December 2018 and May 2019, ADRe-p was introduced into three independent pri-
vate sector registered care homes with 158 residents in one Welsh University Health Board
(UHB), unconnected with previous research sites [4,6]. Homes used electronic or paper rec-
ords: all MAR charts were on paper. Prescriptions were issued by GPs and nurse prescribers,
working with specialist teams e.g. community mental health, Parkinson’s disease. Medicines
were dispensed by community pharmacists. These included preparations for minor ailments,
which are normally purchased by ambulatory service users. Patient records are regularly
inspected to ensure they meet the standards of the Care Inspectorate Wales (CIW) https://
careinspectorate.wales/about-us. Inclusion criteria for care homes were:
• Providing residential or nursing care or both to service users meeting inclusion criteria
below.
• Willing to use the ADRe-p Profile in routine practice
• Staff aware of the Mental Capacity Act 2005, and willing to take informed consent.
Residents’ inclusion criteria were:
• Resident at the care home and expected to continue to live there for 1 year
• Currently taking >3 prescribed medicines daily. This definition of polypharmacy is used by
Cochrane reviewers [27]. We were unable to adopt definitions based on appropriateness or
duration of prescriptions before gaining consent to view records.
• Willing and able to give informed, signed consent themselves, or where capacity was lacking,
a consultee was willing to give advice and assent to the resident participating.
Exclusion criteria were:
• age<18
• Receiving active palliative care
• Not well enough to participate, as appraised by their nurses
Our intervention: ADRe-p
ADRe-p engages nurses and carers in the multidisciplinary discussion around medicines man-
agement [2–4]. Searches indicate there is no alternative comprehensive, systematic patient
assessment of problems potentially related to prescribed medicines [3,16,36,37]. ADRe-p is
intended to support care home staff to raise concerns about possible ADRs or ADEs they have
noticed. Supporting information provides possible explanations for observed signs or symp-
toms (Fig 1).
Developing ADRe-p. ADRe was adapted to encompass medicines commonly prescribed
in primary care, including medicines for cardiovascular, respiratory conditions and diabetes,
by addition of seven symptom-related questions, and removal of three. Decisions were based
on an empirical review of the England and Wales patient safety incident reports describing
signs and symptoms of adverse drug reactions [8], and review by our expert advisory group,
including pharmacists, nurses and general practitioners. All ADRe-p items were rated anony-
mously by three pharmacists and two nurses. All items were rated important and 93/102 as of
the highest importance to delivery or outcomes of care. (Changes from ADRe to ADRe-p are
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listed in Table A in S2 File). ADRe-p was cognitively tested with two service users and one care
home employee to ensure understanding. Sixteen suggestions were made: seven were adopted
on ADRe-p, and nine were accommodated in the supporting information for carers and
nurses.
Approach and recruitment
Following ethical approval, February 2018, all 27 care homes in one district of the UHB were
contacted by their pharmacist, and agreed to telephone contact by the researcher. When inter-
est was expressed, researchers visited and provisionally arranged for adoption of ADRe-p,
whilst the sponsor (the UHB) prepared research contracts for the universities and care homes.
When the 171 page contracts (including a 150 page protocol) for care homes were ready,
December 2018, the researcher revisited to confirm each home’s participation. The homes
reviewed their contracts, completed their details and passed them to the sponsor. They then
received a final version for signature. Participating nurse leads were briefed by researchers,
who joined team meetings to discuss implementation. Residents and service users were
screened for eligibility and recruited by their nurses (see Ethics). Care home staff were invited
to participate in serial interviews, and service users, pharmacists and GPs to single post hoc
interviews.
Outcome measures
1. Changes in signs and symptoms possibly related to adverse effects of prescribed medicines,
as recorded on ADRe-p, using residents’ notes as supplementary information.
2. Prescription changes in the same timeframe, as recorded on MAR charts.
3. Multidisciplinary medicines optimisation.
4. Costs of administering ADRe-p and changes in resource use resulting from ADRe-p
administration. Costs were based on 2018/19 price year and taken from the Personal Social
Services Research Unit (PSSRU) Unit Costs of Health and Social Care [38].
Sample size
We had planned a larger study, but were unable to recruit. We had hoped to introduce medi-
cines’ monitoring into seven care homes, each with 26 residents prescribed >3 medicines
(estimated 90% residents). Previously, with participants acting as their own controls, de-pre-
scribing occurred in 8.5% more participants (12.1% vs. 3.6%) when ADRe Profiles for mental
health medicines were used. We hypothesised that ADRe-p would be twice as effective as its
predecessor for mental health medicines. Based on the reported intra-cluster coefficient (0.02)
[6], 182 participants were needed to detect this difference with 80% power and 5% significance
[39], allowing for 5% loss to follow up. The sample size is not based on the primary outcome
(clinical gain) because all participants in the 2015 trial had several clinical gains recorded [6].
Data collection
The care home records were examined before and after the introduction of ADRe-p to identify
any changes in health status and signs and symptoms of potential ADRs (HP, SJ). Serial
ADRe-ps administered by care home staff (at least two per resident), including pharmacists’
comments, and MAR charts were copied, and collected by researchers. Problems and lists of
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prescriptions were transcribed, and changes between the first and final ADRe-p were noted.
HP and SJ collected and analysed data.
Analysis
Data were entered into excel via the electronic version of ADRe-p, imported into SPSS version
26 [40], checked and described for first and last ADRe-p profile administrations. To explore
the recorded changes and potential for further clinical gains, putative aetiologies of residents’
signs and symptoms were ascribed, using clinical information from care home records, includ-
ing, but not restricted to, information on ADRe-p, and MAR charts, and checked by all
authors using manufacturers’ literature and formularies. Juxtaposition of ADRe-ps and MAR
charts generated suggestions for changes to improve the processes and possibly the outcomes
of care. The prevalence of problems on the first and last profiles was compared with two by
two contingency tables, using McNemar’s test for related dichotomous variables [41].
All interviews were uploaded via digital media for transcription using a standard operating
procedure (SOP) to ensure confidentiality. Interviews were transcribed verbatim and anon-
ymised. Transcripts were thematically analysed alongside the data of all 19 completed cases, to
identify, analyse and report patterns within data [42]. Two researchers (HP, SJ) ensured valid-
ity of the analysis and verified interpretation. Disagreements were resolved through discussion.
Interviews and case reports were integrated with outcome measures documented on ADRe-p
to enhance understanding and validity, and contextualise the ADRe-p data [43,44].
Ethics
The local NHS Research Ethics Committee approved the study on 19th December 2017, and
gave final clearance on 27th February 2018 (reference number 17/WA/0391, IRAS ID 237933).
The Research and Development (R&D) department of the sponsoring UHB approved project
start on 18th September 2018. Honoraria of £400 were paid to participating homes to cover
costs, including staff time expended recruiting participants, liaising with researchers, and
using facilities such as copiers.
Written and verbal information was offered to all potential participants. Written informed
consent was obtained for all data collection, including completion of ADRe-p within routine
care. Residents meeting inclusion criteria were approached by both registered nurses and car-
ers and asked to consent to researchers reviewing their clinical records, including completed
ADRe-p Profiles and MAR charts. Signed consent was taken by staff fully aware of the Mental
Capacity Act 2005. Where nurses judged that residents lacked capacity to consent, consultees
signed on their behalf; consultees were relatives or professionals not involved in the study,
who were in regular contact with the participants [5,6]. The study was not unduly invasive, in
that it did not expose participants to risks beyond the experiences of daily life or routine medi-
cal examination [45]. All previous participants have benefitted [4–7,46]. All interviewees were
competent adults, and gave signed consent to audio-recording.
Results
Recruitment and retention
Of the 27 homes telephoned, three signed the contract and participated. Ten initially agreed to
participate. Seven dropped out due to delays and complexities of the contracting process or
changes in circumstances or staffing (Fig 2a). Of the 158 residents, 90 were ineligible and 23
were not approached. 16 families found the consenting process too difficult. 26 residents were
recruited, and 19 completed at least two ADRE-ps on separate occasions; two passed on, three
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became too unwell, and two were hospitalised (including a frail lady of 94 with acute kidney
injury prescribed lithium).
Four of the five pharmacists working with the homes reviewed ADRe-p for 7 residents [5
(H2) 2 (H3)], within the study’s timeframe. (Fig 2b) Of 28 interviews planned, 12 were under-
taken and transcribed: service users (2), care home nurses or carers (6 –one twice), carers (2),
pharmacists (3). All GPs declined interviews, asking pharmacists to convey their views, since
they felt that GPs were not directly involved in the study.
Participants. Researchers’ initial impressions of the care homes were spotless floors,
engagement with the community, and acts of kindness from staff. Medicines were invisible,
but were affecting people’s lives. By reading residents’ notes (some 20 electronic files or paper
documents per resident) we were able to glean 10–25% of the information needed to complete
ADRe-p: this took researchers (SJ, HP) ~1 hour per resident per review. For example, seizures,
insomnia, postural hypotension and extra-pyramidal symptoms (EPS e.g. Parkinsonian
Fig 2. a. Care home recruitment: Flow diagram. b. Resident recruitment: Flow diagram.
https://doi.org/10.1371/journal.pone.0244519.g002
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movements for residents prescribed antipsychotics) were only recorded on ADRe-p. ADRe-p
was completed by carers, and copies were passed to registered nurses, pharmacists and
prescribers.
The 19 residents completing two ADRe-ps were aged 35–92 (mean 74.8 [15.2]); 12 were
female. Six were prescribed antipsychotics, eight AEDs, 14 antidepressants (3 prescribed >1
antidepressant), five sedatives, 10 medicines for dementia (3 prescribed >1 medicines in this
class); only one resident (2.7) was prescribed no mental health medicines (Table 1).
Outcomes
1. Clinical gains and relation to intervention. A mean [SD] of 2.93 [1.71] changes were
made to the process of care per resident (range 0–6), including referrals, investigations and
prescription changes (Table 1). For example: nurses were prompted to directly request GP
reviews of medicines (6), and signs and symptoms, including extra-pyramidal symptoms
(EPS), tremors, sleep problems, dehydration, and pain were recorded for the first time. Clinical
gains were identified for 17/19 residents (mean 3 [1.67], range 0–7) (Table 1). Examples
include: 6 residents no longer in pain, 3 no longer experienced convulsions, 1 had dyspnoea
treated, laxative prescribing was adjusted to reduce diarrhoea for 2, falls ceased for 2 (of 4
noted as falling and of 5 able to stand). As carers became more familiar with some problems,
such as EPS, they were more likely to record them (Tables B & C in S2 File).
Fewer residents experienced pain and confusion, and some residents became free of diar-
rhoea (4), asthenia (4), insomnia (4), aggression (3), swallowing difficulties (2), falls (2) and
seizures (3). Few new problems arose, and no clinical deterioration was noted. However, not
all problems were solved for all residents (Table 2).
The improvements in outcomes were diverse, and some (e.g. xerostomia, constipation, rest-
lessness) were recorded only for a single resident (Tables B & C in S2 File). (Gains are listed in
Table 3). The carers explained how they achieved these improvements, for example:
“ADRe-p is a prompt to go further with the GPs, and obviously give nurses a better under-
standing and question: do you think this could be from medication? A resident (1.3) had a
rash, now we said: they’ve got a rash do you think it could be from medication? So you auto-
matically look a bit deeper than you would’ve before. (. . .) One resident (1.3) had an all-over
rash, it was quite aggressive and then obviously when the GP came we were saying: she’s on
this medication and it’s prompted us to go through this because of the ADRe-p, and then
they worked with us on obviously identifying what the rash could be and giving the correct
Table 1. Summary of outcomes for residents (n = 19).
Observations Numbers of: Mean [SD] Median [25th to 75th centile] Range (min-max)
Problems identified/resident 1st profile 15.84 [4.41] 16 [14–19] 19 [6–25]
Problems identified/resident last profile 14.05 [4] 13 [11.5–16] 14 [8–21]
Changes to care by nurses/resident 2.93 [1.7] 3 [2–3.5] 6 [1–7]
Positive outcomes of care (clinical gains)/resident 3 [1.67] 3 [2–4] 7 [0–7]
Suggestions/resident from researchers 5.11 [1.76] 5 [4–6] 8 [2–10]
Medicines prescribed 1st profile 15.11 [4.1] 14 [12–17] 14 [10–24]
Medicines prescribed 2nd profile 14.95 [4.65] 13 [11.5–19.5] 17 [7–24]
SD standard deviation.
https://doi.org/10.1371/journal.pone.0244519.t001
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medication to address the rash.” (. . .) the study has helped us identify little bits to push
forward.”
(Carer, H1).
This sentiment was endorsed by pharmacists. The changes in medicines and problems are
recorded in Table C in S2 File.
Not all residents’ problems were addressed by the time of final record review (Table 2).
Researchers made two to ten further suggestions per resident (mean 5.11 [1.76], Table 1). For
example: three residents with hypotension (SBP<110mmHg) were prescribed antihyperten-
sives (1.1, 1.2, 3.8), and, of six residents prescribed antipsychotics for >6–8 weeks, five had evi-
dence of extra-pyramidal symptoms (EPS) (one also experienced insomnia when risperidone
was given nocte). Two residents (both prescribed risperidone) had no improvements in out-
comes, but we noted how some problems might have been addressed, for example, by adjust-
ing analgesia or administering risperidone mane (Table 4 gives details).
2. Prescription changes. At least one medicine was discontinued for seven of 19 residents,
and doses reduced for a further five. For example, zopiclone was de-prescribed for two, and
senna and paracetamol were changed to PRN (pro re nata) (one each). Medicines were added
or increased for nine residents. For example, two had skin conditions treated, and one (2.2) a
salbutamol inhaler prescribed, alleviating dyspnoea. Overall, prescribing was reduced from
Table 2. ADRe-p Profile items and responses: Observations and questions.
Item on ADRe-p profile Problem on final
profile
P� Unadjusted OR 95% CI
No Yes
Bowel control Problem on 1st profile No 14 1 0.38 ��
Yes 4 0
Low energy Problem on 1st profile No 9 1 0.38 11.25 0.97–130.22
Yes 4 5
Sleep problems Problem on 1st profile No 12 0 0.13 ��
Yes 4 3
Aggression† Problem on 1st profile No 12 0 0.25 ��
Yes 3 3
Confusion Problem on 1st profile No 7 1 0.38 12.25 1.08–138.98‡
Yes 4 7
Pain Problem on 1st profile No 6 0 0.03‡ ��
Yes 6 7
Swallowing difficulties Problem on 1st profile No 14 0 0.25 ��
Yes 2 3
Falls Problem on 1st profile No 15 0 0.50 ��
Yes 2 2
Seizures Problem on 1st profile No 16 0 0.25 ��
Yes 3 0
�McNemar’s test for related dichotomous variables, assesses change in response in both directions.
��Odds ratios could not be calculated due to zero in cells. This happened where the problems were addressed by the final profile.
†Missing data detailed in Tables B & C in S2 File. Cases with any missing value removed.
‡statistically significant.
https://doi.org/10.1371/journal.pone.0244519.t002
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Table 3. Clinical gains for residents: Comparison of first with final ADRe-p profiles (n = 19).
Resident
ID Age Clinical changes
1.1 85–89 F Outcomes of care
1. Pain no longer present: paracetamol now given when needed.
2. Heartburn and anorexia resolved when iron discontinued.
3. Confusion and sedation appear to have resolved, possibly because appetite has recovered and
heartburn is no longer troublesome at night.
Process of care
1. Gabapentin stopped when study was announced, before data collection: this likely ameliorated
confusion.
1.2 60–64 M Outcomes of care
1. Pain no longer present. This is probably due to regular analgesia, rather than relying on PRN
requests from an inarticulate resident. However, the extra codeine may be causing sedation.
2. Seizures no longer reported, possibly due to improved pain management.
3. Swallowing difficulties resolved.
Process of care
1. Dietician review.
2. ‘Flu immunisations completed.
3. ADRe-p was the only record of vital signs.
1.3 65–69 F Outcomes of care
1. The rash has resolved, probably due to the newly prescribed Piriton™.
2. Seizures and
3. aggression resolved. AEDs were being given same time as bulk laxative. Therefore, AEDs
started to work when bulk laxative stopped.
4. Diarrhoea & double incontinence ceased, likely due to discontinuation of bulk laxative.
5. Swallowing difficulties and
6. Painful gums have resolved, likely following assessments triggered by ADRe-p.
Process of care no change
1.4 70–74 F Outcomes of care
1. Hypotension and
2. Incontinence appear to have resolved. This may be due to the reduced bioavailability of
generic galantamine (there has been a generic substitution for Luventa1).
3. Swallowing difficulties have resolved, but not clear if this is related to ADRe-p.
Process of care
1. Scalp itching is now being treated.
2. Vitamin D now prescribed for fracture prevention/general health.
1.5 80–84 F Outcomes of care
1. Restlessness, aggression,
2. Pain, constipation, broken skin & missed meals were not recorded by profile 3.
3. Regular (not missed) meals probably corrected hypoglycaemia, thereby improving agitation
and aggression. Likely, ADRe-p drew attention to the missed meals.
Process of care
1. Extra-pyramidal symptoms (EPS), nausea and dehydration were recorded for the 1st time. EPS
were probably due to risperidone, which has been prescribed for >8 weeks: delayed onset of
EPS, particularly tardive dyskinesia (jerky movements now seen) is usual.
2. OT referral: OT requests behaviour support, but doctor says this is unhelpful.
1.6 >90 F Outcomes of care
1. Weakness and
2. missed meals have resolved. Changing zopiclone to PRN in follow up notes probably helped by
alleviating weakness.
Process of care
1. Doctor asked to review cough—says observe only.
2. Dysphagia screening arranged: advice offered.
3. Medication error (no details found).
4. EPS were being recorded by end of study. Onset may be delayed: a likely cause is a high dose of
duloxetine for an underweight elderly lady.
5. No other records of oxygen saturation.
(Continued)
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Table 3. (Continued)
Resident
ID Age Clinical changes
2.1a 35–39 F Outcomes of care
1. Pain resolved by study end. Paracetamol & ibuprofen administration appear to be less frequent.
2. Behaviour appears to have eased, but anxiety remains.
3. Seizures appear controlled.
Cognitive decline may have stabilised.
Process of care
1. Resident prescribed carbamazepine and immobile. Accordingly, pharmacist requested vitamin
D intake to be discussed with doctors, but no action by study end. (Potential fracture
prevention.)
2.2a 70–74 F Outcomes of care
1. Dyspnoea has resolved now that asthma is treated.
2. The resident is no longer in pain. This may be due to the reduction of rivaroxaban (indication
without aspirin not clear) or the decision to change the suprapubic catheter q.4 weeks, not q.
8–12.
3. Suprapubic catheter no longer blocking.
4. Rash has resolved: cause uncertain but likely the reduced dose of anticoagulant.
5. FBC reported as normal. Iron discontinued.
Process of care
1. ADRe-p was the only record/documentation of oedema or tremors.
2. A new eye-care preparation has been prescribed.
2.3a 65–69 M Outcomes of care
1. Seizures reported pre-study are no longer present. A consultant letter requested
documentation of seizures. 6 months later, after start of study, a record of seizures has been
introduced & 2.3a is now free of seizures. Macrogols (Laxido1) are given less often: it appears
they were co-administered with AEDs, reducing effectiveness of AEDs.
2. Lost 5kg weight, BMI reduced from 33 to 31.5.
3. Diarrhoea no longer present, likely due to reduced laxative administration.
4. Frustration no longer reported, uncertain whether ADRe-p, improved seizure control, dental
extraction, end of diarrhoea have helped with this.
Swallowing difficulties no longer reported.
Process of care
1. Dental extraction, but pain persists.
2. Risk of dehydration reduced, possibly due to decreased bulk laxatives.
2.4a 40–44 F Outcomes of care
1. Diarrhoea resolved now laxatives only PRN, following pharmacist’s advice.
2. BP,
3. BMI and
4. Confusion have improved now pregabalin dose reduced.
Process of care
1. ADRe-p is the only record of vital signs.
2.6b 80–84 M Outcomes of care
1. Falls no longer a problem. This may be attributed to the medication changes and pharmacist
review, particularly reduced dose of antipsychotic & reduced anticholinergic burden as
promethazine discontinued plus zopiclone discontinued. Aripiprazole is noted as being
sedative & causing insomnia, and making administration nocte might have helped.
2. BMI improving and not regarded as a problem now that nutrition supplement is prescribed,
aripiprazole reduced & anorexiant discontinued.
Process of care no change
2.7d >90 F Outcomes of care
1. Sleep,
2. balance and falls have improved, possibly due to regular administration of nutrition
supplements.
Process of care
1. Possible hypothyroidism explored by pharmacist.
2. Medicines are no longer missed, which may account for the appearance of agitation or
indigestion.
(Continued)
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Table 3. (Continued)
Resident
ID Age Clinical changes
2.8b 80–84 F Outcomes of care
1. Gait appears to be improved now the opioid and hypnotic have been discontinued following
pharmacist review.
2. Convulsions and panic attacks are no longer reported, and this may be due to discontinuation
of buprenorphine (a rare ADR).
3. Hypertension appears to have resolved, and this may be related to discontinuation of
paracetamol.
Process of care no change
3.2 80–84 M Outcomes of care no change (only 6 problems listed)
Process of care
1. Dental problems identified.
2. Codeine increased to treat pain, but ineffective.
3. FBC indicating anaemia reported, but not linked to poor healing. No actions.
4. Medicines administered regularly.
5. Tablets no longer crushed.
3.3 80–84 F Outcomes of care
1. Pain now confined to 1 shoulder.
2. Benefits of bringing prescribing of dopamine agonists into line with guidelines are yet to be
fully realised.
3. Insomnia no longer a problem.
4. Incontinence appears to have resolved.
Process of care
1. ADRe-p provided the only record of posture and movement disorders. This has triggered
medicines review. After Profile 1, the nurse asked the GP to review medicines. The GP
contacted the Parkinson’s nurse and the mental health nurse to do these reviews. The home
was requested to monitor resident, but there were no specifications.
2. Dopamine agonists were increased to address tremors and the gap in administration has been
closed from 16 to 8 hours (sup info p.9): the only evidence of effectiveness is pain reduction.
3. Falls risk reassessed by study end.
4. GP & mental health nurse disagreed as to whether to use lorazepam PRN or quetiapine. The
care home nurses became actively engaged in the decisions, and consulted by prescribers.
5. Need for calcium and vitamin D supplements highlighted by pharmacist.
3.6 75–79 M Outcomes of care
1. Symptoms of anxiety and tiredness have abated, but aggression remains.
2. Dry mouth has improved, explaining why appetite has returned.
Process of care
1. GP contacted and resident reassured regarding visual hallucinations (dopamine agonists
prescribed).
2. Overuse of senna has been curtailed.
3. Dehydration risk is now recognised.
4. Missed doses are highlighted.
3.7 75–79 F Outcomes of care no change
Process of care
1. Assessed with Abbey pain scale.
2. April 2019, nurses requested meds review. May 2019, GP reports no EPS, and risperidone
continued.
3. Unresponsive episodes reported for the first time: no MDT engagement by study end.
(Continued)
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mean 15.1 [4.1] to 14.9 [4.7] items/resident, including emollients and nutritional supplements
(Table 1). Examples of changes are listed in supplementary file Table C.
Prescription changes were brought about by: nurses requesting GP reviews (six residents:
2.6, 2.8, 3.6, 3.7, 3.8, 3.0); pharmacists actively engaging with ADRe-p (Fig 1); routine contact
with GPs and non-medical prescribers (1.4, 1.6, 3.2, 3.3); nurses managing symptoms via exist-
ing PRN orders (1.6, 2.4, 3.8) (Table 3)
“Helps us identify reactions to medication, which prompted us to go to the GPs, have a better
understanding, and being able to challenge the GP.”
[H1, N2].
However, most medicines were unchanged, but not necessarily unchallenged, during the 3
months of the study, and repeat prescriptions were the norm (Table C in S2 File has examples).
A concerned service user related to her mother’s care in another home:
“Her head down. . . they tell me it’s the side effects of antipsychotics (. . .) this [study] is a good




ID Age Clinical changes
3.8 85–89 F Outcomes of care
1. Restlessness,
2. hallucinations, panic attacks and aggression have improved, probably due to medication review
requested.
3. Xerostomia has improved, possibly due to prescription changes.
Process of care
1. GP asked by nurses to review meds at start of study: mirtazapine dose split, diazepam changed
from regular to PRN.
2. April 2019, GP asked to review edoxaban for bruising & nosebleeds, but continued
anticoagulant. Again asked to review May 2019 and sertraline increased to 100mg. Different
GP each time. ADRe was the only report of blood loss identified.
3. Dehydration risk recognised and addressed.
3.10 80–84 M Outcomes of care
1. Pain has improved.
2. Constipation and bowel control have improved, likely due to deprescribing co-codamol,
Laxido1 and enema.
3. Oxygen saturation is marginally improved, which might be attributable to stopping zopiclone.
Process of care
1. Co-codamol has been discontinued following medicines review.
2. Active review of bowel control: Laxido was noted as a cause of diarrhoea, and this has been
stopped.
3. Fenbid1 gel stopped.
Home 2 was divided into units specializing in caring for people with dementia (2b, 2d) and adults with physical
disabilities (2a).
https://doi.org/10.1371/journal.pone.0244519.t003
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Table 4. Residents with no recorded clinical gains.
Resident 3.2 (male, aged 80–84) Pain remains
Problems ADRe-p profile 1 Possible causes
BMI 35 Risperidone
Broken skin/poor healing (leg ulcers) Worsening heart failure, obesity, risperidone
Pain Risperidone, statin, possibly gout from furosemide.
Vision problems (cataract) Risperidone
Urinary retention Risperidone, diuretic, rivastigmine, and/or opioids
Long term urinary catheter
Tablets crushed—now resolved
Medicines not taken at same time each
day—now resolved.
Medicines first and final review–no changes
• Apixaban 2.5mg tabs, take 1 2x a day (morning & teatime 5pm)
• Bisoprolol 1.25mg tabs, take 1 each day
• Codeine Phosphate 15mg tabs, take 1–2 up to 4 times a day when required? Given
• Epaderm1 cream, apply daily
• Evacal1 D3 chewable tab, take 1 2x a day (morning & teatime 5pm)
• Furosemide 40mg tabs, take 1 in the morning
• Laxido1 Orange oral powder, take 1 a day in water 8 given
• Omeprazole 40mg gastro-res cap, take 1 daily
• Optiflo1 S 0.9% sterile soln, not given
• Paracetamol 500mg tabs, take 2 every 4–6hrs when required. Given frequently.
• Risperidone 500mcg tabs, take half in the evening
• Rivastigmine 3mg caps, take 1 2x a day (morning & teatime 5pm)
Simvastatin 40mg tabs, take 1 in the evening
Pharmacist’s recommendations: FBC shows HB at 119, slightly low
Researchers’ suggestions for discussion:
1. Pain remains: it is not responding to codeine, which is likely causing constipation, and is not recommended for
people with dementia.
Has gout been considered (furosemide is prescribed)?
Risperidone can cause joint disorders and stiffness and, therefore, pain.
2. 2 antihypertensives are prescribed whilst BP is 116/67, 110/68mmHg on standing: consider postural hypotension.
Beta-blockers are not recommended for people with dementia, but any reduction will need to be gradual.
Furosemide likely essential.
3. Attempts to break a 500mcg risperidone tablet are unlikely to give even doses—liquid is available. Tablets are
film-coated.
4. Risperidone is indicated for 6–8 weeks in the elderly with persistent aggression (not noted as present).
(Interaction with furosemide and risk of CVA, see manufacturer’s literature). It may be contributing to weight
gain and worsening heart failure.
5. Consider risk of catheter blocking if using calcium (vitamin D alone is not a risk).
6. Urinary retention is reported: consider risperidone, rivastigmine, codeine as possible causes.
Resident 3.7 (female, aged 75–79) Behaviour Difficulties
Problems ADRe-p profile 1 Possible causes
Temp 35.7 Incomplete contact between thermometer and skin
BMI 28 Cetirizine & mirtazapine can increase appetite
Unable to stand Illness, memantine, and/or donepezil (dizziness)
Abnormal posture—not on last profile Risperidone, cetirizine (rarely), sertraline (neuromuscular dysfunction),
and/or memantine (balance)
Immobile Illness, risperidone, memantine, and/or donepezil
Dementia/cognitive decline Illness, cetirizine, and/or risperidone
Behaviour problems Risperidone, cetirizine, sertraline, mirtazapine, and/or donepezil
(Continued)
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3. Making it happen: Multidisciplinary medicines optimisation. Much was achieved by
modifications to nursing care, despite “everybody being so busy and very uptight” (N1 H2). For
example: changing a supra-pubic catheter every 4 rather than 8 weeks (2.2) addressed the
problems of frequent blockage and alleviated pain; recording EPS to inform GP of problems
(3.3); or improving intake (five residents). Nurses followed their usual practice of contacting
GPs with concerns.
Table 4. (Continued)
Physical violence Mirtazapine and risperidone can exacerbate symptoms of psychosis.
Risperidone dose received is uncertain, as a 500mcg tablet is halved
Aggression Donepezil, mirtazapine (rare). Hypoxia, sertraline, risperidone
(akathisia), and/or memantine (psychotic disorder)
Agitation/anxiety Risperidone, mirtazapine, sertraline, donepezil, and/or cetirizine
Confusion Cetirizine, mirtazapine, memantine, risperidone. Attributed to dementia
Mood fluctuations Attributed to dementia. Sertraline, mirtazapine, risperidone, donepezil
Insomnia Risperidone mane, donepezil, cetirizine, and/or mirtazapine
Vision problems (glasses) Risperidone can blur vision
Incontinent Donepezil, risperidone. Not clear if retention an element
Unresponsive episodes Idiopathic, memantine, donepezil and other epileptogenic medicines
Medicines first and final review–no changes
• Cetirizine 10mg tabs, take 1 daily
• Co-Codamol 30mg+500mg tabs, take 2 4x a day when required not used
• Conotrane1 0.1%+22% cream, not given apply to affected area
• Donepezil 10mg tabs, take 1 at night
• Duraphat1 5000 toothpaste, use 2x a day
• Hydromol1 ointment, not given apply to skin or use as soap substitute
• Ibuprofen 5% gel, apply up to 3x a day
• Loperamide 2mg caps, take 2 & then 1 after each bowel movement as required not used
• Lorazepam 1mg tabs, take half each day when required not used
• Macrogol1 compound oral powder, take 1 sachet in water each day when required 1 given
• Memantine 20mg tabs, take 1 at night
• Mirtazapine 30mg tabs, take 1 at night
• Risperidone 500mcg tabs, take half at night
• Sertraline 100mg tabs, take 2 each day
Pharmacist’s recommendations: none found
Researchers’ suggestions for discussion:
1. Risperidone reaches peak absorption 1–2 hours after ingestion, and causes insomnia in >1 in 10 recipients
(manufacturer’s literature), as here. Therefore, should be given mane. Use appears to have exceeded 6–8 weeks.
2. Use liquid risperidone to avoid splitting tablets and ensure even dosing, particularly in view of behaviour
problems.
3. Indication for cetirizine (anti-muscarinic) not clear, as no skin problems or hay fever noted (in March); review
might reduce the anti-cholinergic burden and associated confusion and behaviour problems.
4. Sertraline is maximum dose; given the possible association with aggression, consider benefit to harm balance.
5. There is no diagnosis of epilepsy, but the unresponsive episodes and behaviour problems indicate a need to
consider this diagnosis, particularly as memantine, donepezil, anti-depressants and anti-psychotics can cause or
predispose to seizures.
6. Both anti-dementia medicines are recommended as monotherapy. The clinical benefit of the combination might
be considered: memantine may be worsening respiratory or cardiovascular deterioration; oxygen saturation is
borderline and likely contributing to confusion.
Co-prescribing of loperamide and Macrogol1 appears incongruous, but administration records appear appropriate.
Note to Table 4: Problems underlined were not present on last profile.
https://doi.org/10.1371/journal.pone.0244519.t004
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Where pharmacists engaged, residents benefitted e.g. by becoming free of falls (2.6, Fig 3a)
or diarrhoea (Table 3, 2.4: 2 laxatives changed to PRN from regular administration). Pharma-
cists explained how pressures on the services militated against communication and GP
involvement, and ADRe-p filled this hiatus in communications, particularly with non-verbal
patients:
“The GPs are busy; the nurses are busy, sometimes. The GPs head over [to care homes] when
they can, at the end of their clinics. The nurses might’ve been stressed all morning, they are try-
ing to explain themselves to the GP, the GP is trying to obtain a really good thorough history
and it’s difficult. Whereas, if you’ve got one of these [ADRe-p], you could just cross-reference,
and be like “this is what I was concerned about, see”. So yeah we were saying it is a really use-
ful tool.”
P1, H2.
Fig 3. a. Linking problem to solutions, example 1: ADRe’s information used—no more falls. b. ADRe’s information not used—nosebleeds continue. Medicines
underlined were discontinued or reduced. Medicines italicised were started or increased. Aetiologies emboldened were the most pertinent to the resident.
https://doi.org/10.1371/journal.pone.0244519.g003
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Repeated use made ADRe-p easier and quicker “5–15 minutes total”, N1, H3), and engen-
dered a virtuous circle of learning, recognition and knowledge application:
“. . . the more the nurses fill out these things, the more in their mind it’s going to be, they’ll
know what the side effects are (. . .) they’ll see something and automatically associate.”
P2, H2.
“. . .empower them [nurses] to say ‘this has changed, and look I’ve got proof’”. (. . .) “Like me,
the GP might go in and see the patient for a snapshot of time, but the nurses are there with the
patients a lot more than we are.”
P1, H2.
However, not everyone fully engaged, largely due to pressure of work, and some problems
went unattended. For example, when nurses asked the GP to review prescriptions of anticoag-
ulants for resident 3.8 with nosebleeds and bruising, the GP added sertraline (indication not
identified), which increases risks of haemorrhage (Fig 3b). Similarly, a resident with infections,
a tracheostomy and suprapubic catheter was prescribed a high dose of pregabalin (450mg
daily, presumably for pain or anxiety), which predisposes to infections (2.2). Where pharma-
cists did not engage, time pressures meant that complexities were sometimes overlooked. For
example, a lady of 65 (1.3) with seizures was administered antiepileptic drugs (AEDs) simulta-
neously with bulk laxatives; when diarrhoea was noted on ADRe-p, laxatives were reduced and
seizures ceased, possibly because the AED was then fully absorbed.
There were sometimes multiple prescribers. No formal communication systems between
prescribers and carers and nurses giving daily care were observed. ADRe-p acted as shared
documentation, and provided the only record of signs and symptoms indicating possible
ADRs. ADRe-p encouraged nurses to seek medication reviews. For an 81-year-old with Par-
kinson’s disease and antipsychotic prescriptions (3.3), the GP contacted the Parkinson’s nurse
and the mental health nurse to do these reviews. The home was asked to monitor the resident,
but there were no specifications: ADRe-p filled this gap. The Parkinson’s nurse increased
dopamine agonists to address tremors and the overnight gap between administrations was
narrowed from 16 to 8 hours (ADRe’s supplementary information p.9). Pain decreased, as Par-
kinsonian stiffness resolved. There were discussions as to whether lorazepam as required
(PRN) or quetiapine should be prescribed for behaviour problems. ADRe-p (and Supporting
information) empowered the nurses and carers to join these discussions.
4. Economic costs and benefits of ADRe-p. We tested whether ADRe-p could be intro-
duced to support existing routine care in homes, and demonstrated that many, but not all,
ADRs are prevented when ADRe-p is used. Pharmacists confirmed that ADRe-p was address-
ing common problems
“. . .umpteen blood pressure medicines, blood pressure in their boots, giddy and falling, and
nobody ever questions it, whereas using these forms (. . .) will keep everything in an easy for-
mat (. . .) make the nurses think.”
(P1 H2).
Administration of ADRe-p took nurses or carers 5–15 minutes and pharmacists 10 minutes
per resident per month, introducing additional demands on staff time. However, this cost is
minimal, and experience with ADRe-p leads to more efficient completion, keeping costs low.
To estimate costs, we assume a Band 6 Community Nurse, at a rate of £46 per hour (including
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salary and on-costs), undertakes all ADRe-p related activity. Costs include an initial review of
resident taking ~30 minutes, (up to 1 hour if blood tests are included) (£23–46) plus 15 min-
utes per ADRe-p re-administration (£11.50). If ADRe-p is used monthly, it will cost £184 per
resident in the first year and £138 in subsequent years. If ADRe-p is administered by a care
home worker with an hourly salary of £23, as here, then administration costs fall to £92 in year
one and £69 in subsequent years [38].
Use of ADRe-p may also lead to increased contacts with GPs. However, these additional
time costs were again minimal. An additional GP contact would incur a cost of £39 per patient.
Nurses discussed ADRe-p with GPs either at scheduled contacts or as a direct result of ADRe-
p. Pharmacists took 10 minutes to review ADRe-p: costs of a Band 6 pharmacist are estimated
at £46 per hour or £7.67 for a ten-minute review [38].
Health improvements reduced resource use: for example, three patients had changes in
medicines that eliminated seizures, and two patients no longer had falls; both reduced seizures
and falls will likely lead to fewer avoidable hospital admissions. A fall that results in an inpa-
tient admission, perhaps for an intermediate hip procedure for trauma with no or minimal
complications, would cost £3,284, plus additional costs for post-discharge care and rehabilita-
tion. Even where there is no serious injury arising from a fall, attendance at A&E with a Cate-
gory 2 Investigation with Category 1 Treatment (£155) costs slightly less than the annual
administration cost of ADRe-p when completed by nurses, and is more than the annual cost if
ADRe-p is completed by care staff. Through improved health and reduced falls, ADRe-p has
significant potential to both improve patient health and lower health system costs overall. For
more serious adverse events after a fall cost-savings would be even greater.
Discussion
We aimed to identify changes following nurses’, carers’ and pharmacists’ use of ADRe-p.
Introduction of ADRe-p was followed by reduction in pain, seizures, falls, diarrhoea, dyspnoea
and other symptoms for most residents, but more might have been done in some instances.
Clinical gains were identified for 17/19 residents. Examples included: six residents no longer
in pain, three seizure-free, one breathing easily, laxative prescribing adjusted to reduce diar-
rhoea for two, falls ceased for two (of four falling). ADRe-p collated patient information to
minimise ‘undesirable’ signs and symptoms, optimise prescribing, and prevent medicines-
related harm. It prompted multidisciplinary team engagement to address pain, usually by ame-
liorating stiffness or drawing attention to PRN regimens. However, there were instances of
under-prescription of analgesia, as in other vulnerable populations [47]. Only careful review of
medication records and patient history identified likely causes and candidate medicines for
de-challenge (Fig 3a and 3b). However, sometimes, multidisciplinary teams felt too time-pres-
sured (and stressed) to engage with the study, prescribing cascades [48], and the associated
complexities presenting apparently insoluble problems [49].
Bringing residents’ and carers’ voices into the multidisciplinary team
ADRe-p captures patients’ perspectives and enhances patient-centred professionalism by
direct questioning and profiling problems. Similar electronic patient self-report of selected
symptoms is used by oncology trialists [50]. There are no short cuts to “asking the patient spe-
cific questions” [51] p.13, to generate shared documentation [52] and shared decision-making
on medicines optimisation [53]. ADRe-p achieves this by initiating the dialogue needed to cap-
ture signs and symptoms. It also ensures patients receive information on ADRs, and helps pro-
fessionals to attach the same importance to ADRs as patients do [54]: ADRe-p was welcomed
by service users.
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These findings echo those elsewhere: patients benefit when, together, professionals engage
with the detail, complexity and totality of their problems. The initial time invested with
patients leads to longer-term clinical gain and easier nursing [4–6,55]. Replication of findings
in other settings and contexts strengthens the logical inferences to be drawn from geographi-
cally limited work [34,56]. Although human factors, leadership, organisational culture and
multidisciplinary team-working vary between care homes and health boards [57], ADRe
achieves similar outcomes.
A difficult and orphaned task
Disengagement from medicines and their complexities remains a challenge to be addressed by
medicines optimisation [58]. The GMC [59] p.9 advises doctors: “When you issue repeat pre-
scriptions or prescribe with repeats, you should make sure that procedures are in place to
monitor whether the medicine is still safe and necessary for the patient.” (P.9, point 59). How-
ever, the Care Quality Commission [60] p.16 report that patients in care homes are not moni-
tored because there are no systems to support the process, and professional responsibilities for
this are not defined. This may, in part, be attributed to the uncertainty regarding nurses’ roles
in several aspects of medicines management [61], including engagement in monitoring, identi-
fying and reporting potential ADRs [62].
De-prescribing in care homes is difficult, time-consuming, perceived as excessively high-
risk [63] or thwarted by staff shortages [64]. Staff shortages were commonly cited as reasons
for non-participation. However, in practice, completion of ADRe-p took carers or nurses 5–15
minutes and pharmacists 10 minutes per month. To succeed, despite organisational and pro-
fessional barriers, discussions around de-prescribing need to be formalised and integrated into
routine care [53]. Involving the staff spending most time with residents—nurses and carers—
is crucial, and ADRe-p offers a feasible structure for enfranchisement and democratisation of
medical knowledge [65].
Some 10% of healthcare is harmful, and 30% is wasted: identifying the 10% requires change
[66], but change is more difficult where information is complex [49]. ADRs and prescribing
cascades are hard to detect [47], and medical science remains unapplied [67]. Full evaluation
of possible causes of residents’ signs and symptoms requires close attention to the details con-
tained in the ‘undesirable effects’ sections of SmPCs (Table 4, Table D in S2 File). Some resi-
dents are reportedly too poorly to realise any clinical gains [68], but ADRe’s detailed symptom
checking led to symptomatic improvement in our residents, when coupled with very dedicated
nursing care (1.3, Table 4).
New ideas in old structures
Demographic changes and increasing prescribing rates are likely to exacerbate ADR-related
problems, but, currently, there is no defined way forward [69]. No alternative strategies to rou-
tinely or consistently check for ADRs have been suggested [69,70], ADR risk prediction tools
are inadequate [71], and there is little evidence that electronic de-prescribing tools improve
clinical outcomes [30]. Unfamiliar knowledge is not always welcomed, particularly by senior
nurses and doctors [72,73], and an organisation’s internally defined reward system determines
which activities are pursued and which neglected [74]. To overcome the invisibility and dis-
engagement with medicines, and ‘kick start’ the initiative, monitoring may need to feature in
external incentivisation or regulatory systems. ADRe-p could help mediate such changes.
Although authorities consider monitoring patients an essential component of prescribing,
no structures are offered [52,59,60]. ADRe-p offers a workable structure, and is needed to sup-
port medicines reviews [2,3,52,60,65,75–77]. The proposed changes in primary care services,
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entailing weekly GP visits to care homes [78,79] will benefit from all information in a single
shared document [52], rather than ~20 computer files.
Limitations and strengths
This was a before-and-after observational study, without comparators. Our earlier randomised
controlled trial demonstrated how ADRe alleviated pain, reduced prescribing of sedatives and
increased nursing actions [6], but did not lead to ADRe-p adoption by policy makers. An
observational approach was considered complementary [74], but we cannot assume post hoc,
ergo propter hoc.
There are 34 definitions of ADRs, some contradictory, and most lacking inter-rater reliabil-
ity [80]; where medicines were de-prescribed, re-challenge was considered an unacceptable
risk. Accordingly, we make no claims regarding the aetiology of signs and symptoms recorded:
ADRe-p only suggests that iatrogenic aetiologies be considered, rather than allow problems to
be dismissed as inevitable consequences of age or disease [48,53]. Similarly, we were unable to
adopt any of the 21 approaches to categorising harm emanating from healthcare-associated
incidents [81], due to the uncertain duration of problems identified.
Limitations of single site work are reported [3,4]: this study was, in part, undertaken to
address this by seeking replication in different geographical locations [56]. Neither we nor the
care homes had access to GP records. Our assessments of the impact of ADRe-p relied on tri-
angulation of completed ADRe-ps, MAR charts, care home notes (containing GP and consul-
tant letters and referrals), fieldwork observations and interviews. Accordingly, our suggestions
are presented as discussion for future work.
Our sample size was smaller than anticipated. This may have been attributable to delays
(above), and a subsequent loss of resources for recruitment. We had originally anticipated sup-
port from an NHS-funded primary care nurse, and goodwill support from academic col-
leagues, but, due to delays in obtaining signatures on contracts, other commitments precluded
participation when required. A minority of homes approached were recruited (3/27). This
may have caused a volunteer bias, as elsewhere [4,82]: homes that declined often cited staffing
issues, whereas those completing did not share these problems, and used zero or few agency
staff. Similarly, of the five pharmacists working with the homes, four engaged in the study, and
they were uniformly excellent.
The study was not designed to capture definitive data on resource use, but the evidence
shows that ADRe-p can improve patient outcomes, and may reduce healthcare costs. ADRe-p
involved existing staff, and therefore had relatively low delivery costs, increasing the cost-bene-
fits of change.
We did not use quality-of-life measures, as we found that these fail to capture important
symptoms, such as pain and emesis, are difficult to administer with people with cognitive
impairment [6], and reviewers indicate that they are infrequently used in this area [28].
Implications
ADRe-p relieved unnecessary suffering for participants. It was the only observed strategy for
multidisciplinary team working around medicines optimisation. ADRe-p prevents ADRs
becoming serious and improves care quality by: a) regular systematic checks and documenta-
tion of problems; b) transfer of information from care home staff to prescribers and pharma-
cists to optimise therapeutic regimens; c) recording change; d) involving the professionals
closest to residents in decision around medicines, doses and timings, and providing them
with supporting information. As the care home sector emerges from the COVID-19
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pandemic, ADRe-p should form a crucial aspect of upskilling and enhanced multidisciplinary
communication.
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